INT5871

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1986
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 38
Total Number 38
Disease Relevance 20.35
Pain Relevance 6.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IFNA2) extracellular region (IFNA2) cell-cell signaling (IFNA2)
Anatomy Link Frequency
brain 4
shields 2
bone marrow 1
immune system 1
thoracic 1
IFNA2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 13 100.00 Very High Very High Very High
narcan 12 100.00 Very High Very High Very High
vaginimus 4 100.00 Very High Very High Very High
addiction 6 99.60 Very High Very High Very High
Enkephalin 5 99.30 Very High Very High Very High
opiate 7 98.72 Very High Very High Very High
Central nervous system 9 98.12 Very High Very High Very High
withdrawal 9 97.48 Very High Very High Very High
methadone 3 97.40 Very High Very High Very High
pain flank 1 97.08 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disease 93 100.00 Very High Very High Very High
Papillomavirus Infection 12 100.00 Very High Very High Very High
Dyspareunia 4 100.00 Very High Very High Very High
Oral Tuberculosis 1 99.98 Very High Very High Very High
Thyroiditis 8 99.92 Very High Very High Very High
Depressive Disorder 1 99.92 Very High Very High Very High
Cervical Intraepithelial Neoplasia 7 99.82 Very High Very High Very High
Drug Dependence 3 99.60 Very High Very High Very High
Death 4 99.56 Very High Very High Very High
Renal Cancer 3 99.42 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This study reports the inhibitory effect of hrIFN alpha on the binding of 3H-naloxone to rat brain membranes in vitro.
hrIFN alpha Binding (binding) of in brain associated with narcan
1) Confidence 0.48 Published 1992 Journal Life Sci. Section Abstract Doc Link 1317938 Disease Relevance 0 Pain Relevance 0.49
The effect of dipyridamole on ME level is suggested to develop via a-IFN interaction with the opioid systems.
a-IFN Binding (interaction) of associated with enkephalin and opioid
2) Confidence 0.42 Published 1990 Journal Biull Eksp Biol Med Section Abstract Doc Link 2143090 Disease Relevance 0 Pain Relevance 0.60
Multifocal metastases of recurrent renal cell carcinoma successfully treated with a combination of low dose interleukin-2, alpha-interferon and radiotherapy.
alpha-interferon Binding (combination) of associated with renal cancer and metastasis
3) Confidence 0.37 Published 2005 Journal Int. J. Urol. Section Title Doc Link 16351657 Disease Relevance 0.89 Pain Relevance 0.14
Interferon alpha-2b treatment of symptomatic chronic vulvodynia associated with koilocytosis.
Interferon alpha-2b Binding (associated) of associated with vaginimus
4) Confidence 0.37 Published 1993 Journal Acta Derm. Venereol. Section Title Doc Link 7904410 Disease Relevance 0.38 Pain Relevance 0.31
Radiation, chemotherapy, and alpha interferon form the core of treatment, with the former two more commonly used.
alpha interferon Binding (Radiation) of
5) Confidence 0.35 Published 1993 Journal Am J Otolaryngol Section Abstract Doc Link 8434721 Disease Relevance 1.16 Pain Relevance 0.09
METHODS: Fifty patients with chronic hepatitis C who had never received alpha-interferon were randomly assigned to receive 3-8 MU of alpha2b-interferon, three times weekly for 6 months, alone or in association with ketoprofen at a dose of 200 mg/day five times weekly.
alpha2b-interferon Binding (association) of
6) Confidence 0.35 Published 1999 Journal Aliment. Pharmacol. Ther. Section Body Doc Link 10540048 Disease Relevance 0.08 Pain Relevance 0
METHODS: Fifty patients with chronic hepatitis C who had never received alpha-interferon were randomly assigned to receive 3-8 MU of alpha2b-interferon, three times weekly for 6 months, alone or in association with ketoprofen at a dose of 200 mg/day five times weekly.
alpha2b-interferon Binding (association) of
7) Confidence 0.35 Published 1999 Journal Aliment. Pharmacol. Ther. Section Body Doc Link 10540048 Disease Relevance 0.08 Pain Relevance 0
The results reported herein coupled with similar findings for alpha-interferon and cyclosporine, suggest that opiate dependence may involve the immune system.
alpha-interferon Binding (findings) of in immune system associated with addiction and opiate
8) Confidence 0.35 Published 1987 Journal Int. J. Immunopharmacol. Section Abstract Doc Link 3623770 Disease Relevance 0.63 Pain Relevance 1.23
[Treatment of multiple angiomatosis involving the skeleton and the abdominal and thoracic cavities with interferon alpha, thalidomide and zoledronate].
interferon alpha Binding (cavities) of in thoracic associated with angiomatosis
9) Confidence 0.35 Published 2008 Journal Vnitr Lek Section Title Doc Link 18672578 Disease Relevance 0.97 Pain Relevance 0.15
Intravesical approaches have failed, such as valrubicin [9], are investigational, such as gemcitabine [10] and mycobacterial cell wall preparations [11], or efficacy should be confirmed, such as the combination of BCG and interferon-alpha 2b [12].
interferon-alpha 2b Binding (combination) of
10) Confidence 0.35 Published 2009 Journal World J Urol Section Body Doc Link PMC2694311 Disease Relevance 0.97 Pain Relevance 0
Human recombinant interferon alpha inhibits naloxone binding to rat brain membranes.
recombinant interferon alpha Binding (binding) of in brain associated with narcan
11) Confidence 0.32 Published 1992 Journal Life Sci. Section Title Doc Link 1317938 Disease Relevance 0 Pain Relevance 0.54
They were then held at that IFN-alpha dosage and rIL-2 was increased to 50,000 IU.
IFN-alpha Binding (dosage) of
12) Confidence 0.32 Published 1992 Journal J. Neurooncol. Section Abstract Doc Link 1541981 Disease Relevance 0.50 Pain Relevance 0.10
Following the widely accepted therapeutic standard of treatment of HCV infection with parenteral interferon alpha, and encouraged by the author's won good experience with orally administered natural human interferon alpha in low doses (leuHuIFN alpha (ldou)), applied to chronic active HBV hepatitis patients, this form of interferon was given to six randomly selected HCV infected patients (2 women, 4 men) aged 34-62 years.
interferon alpha Binding (encouraged) of associated with hepatitis b virus infection, hepatitis c virus infection, hepatitis and infection
13) Confidence 0.32 Published 1993 Journal Arch. Immunol. Ther. Exp. (Warsz.) Section Abstract Doc Link 8129569 Disease Relevance 0.71 Pain Relevance 0
Twenty-four patients with human papillomavirus (HPV)-associated cervical intraepithelial neoplasia (CIN); of whom 13 had CIN 1, 8 had CIN 2, and 3 had CIN 3; were treated with recombinant alpha 2b interferon (IFN) by intraperilesional injections.
recombinant alpha 2b interferon Binding (treated) of associated with papillomavirus infection and cervical intraepithelial neoplasia
14) Confidence 0.31 Published 1992 Journal Sex Transm Dis Section Abstract Doc Link 1326126 Disease Relevance 1.28 Pain Relevance 0.06
A number of steps can be taken to minimize the morbidity associated with IFN-alpha-2b therapy, resulting in an improvement in both QOL and patient compliance.
IFN-alpha-2b Binding (associated) of
15) Confidence 0.31 Published 2005 Journal Cancer Nurs Section Abstract Doc Link 15915059 Disease Relevance 0.46 Pain Relevance 0
Interactions between IFNalpha and noradrenergic system have also been reported.
IFNalpha Binding (Interactions) of
16) Confidence 0.27 Published 2005 Journal Encephale Section Abstract Doc Link 16142050 Disease Relevance 0.45 Pain Relevance 0.56
Optimal duration of therapy with pegylated interferon alpha-2a (40 kDa)
pegylated interferon alpha-2a Binding (duration) of
17) Confidence 0.26 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2426802 Disease Relevance 1.04 Pain Relevance 0.08
In addition, an electrophysiological investigation into the basis of the interaction of opioids and rIFN-alpha in brain structures essential for the expression of opioid activities is also presented.
rIFN-alpha Binding (interaction) of in brain structures associated with opioid
18) Confidence 0.21 Published 1988 Journal J. Neurosci. Res. Section Abstract Doc Link 2449543 Disease Relevance 0.09 Pain Relevance 0.55
Peginterferon-alpha-2a (40 kD) is produced by the covalent attachment of recombinant interferon-alpha-2a to a branched mobile 40 kD polyethylene glycol moiety, which shields the interferon-alpha-2a molecule from enzymatic degradation, reduces systemic clearance and enables once-weekly administration.
interferon-alpha-2a Binding (shields) of in shields
19) Confidence 0.17 Published 2001 Journal Drugs Section Abstract Doc Link 11772139 Disease Relevance 0.22 Pain Relevance 0
Peginterferon-alpha-2a (40KD) is produced by the covalent attachment of recombinant interferon-alpha-2a to a branched mobile 40KD polyethylene glycol moiety, which shields the interferon-alpha-2a molecule from enzymatic degradation, reduces systemic clearance and enables once-weekly administration.
interferon-alpha-2a Binding (shields) of in shields
20) Confidence 0.17 Published 2002 Journal BioDrugs Section Abstract Doc Link 12102649 Disease Relevance 0.22 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox